Trials / Terminated
TerminatedNCT03426345
Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 311 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of relamorelin compared to placebo in participants with diabetic gastroparesis. Participants will report daily severity scores of their diabetic gastroparesis symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo injected subcutaneously twice daily. |
| DRUG | Relamorelin | Relamorelin 10 μg injected twice daily for 12 weeks. |
Timeline
- Start date
- 2018-02-16
- Primary completion
- 2020-07-16
- Completion
- 2020-07-16
- First posted
- 2018-02-08
- Last updated
- 2021-08-06
- Results posted
- 2021-08-06
Locations
240 sites across 15 countries: United States, Argentina, Austria, Belgium, Brazil, Canada, Colombia, Denmark, Germany, Hungary, Latvia, Mexico, Russia, South Africa, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03426345. Inclusion in this directory is not an endorsement.